Tag: ELY

Opinions on $PFE and $ELY

PFE – Pfiser Inc, a global bio-pharmaceutical company, has been on a downtrend since November 2015. Analysts believe the stock is undervalued, especially post the announcement of FDA approval of the drug – Xeljanz XR (tofacitinib citrate)

PFE – Pfiser Inc
Fundamentals Previously closed at 30.01
Day’s high 30.08
Day’s low 29.51
P/E ratio 24.25
EPS 1.24


Analysts opinion PFE has a PEG ratio of 2.42, P/S of 3.79 and a P/B of 2.77. Currently, its forward P/E is 12.15, lower than the stocks in the SPX at 17.
Sentiments Xeljanz XR is the first and only oral treatment for RA (Rheumatoid arthritis), which is a chronic, inflammatory autoimmune disease that causes a range of symptoms, including pain and swelling in the joints, particularly those in the hands, feet and knees. This drug is approved in more than 45 countries in the world, and PFE has huge potential for the drug. According to statistics, 1.3 million Americans have RA, and out of every 100,000 people, 41 are diagonised with RA every year.
 Despite the announcement, the stock had lower sentiments yesterday. Analysts believe that eventually, the market will rise to take into consideration the increased potential of the firm due to FDA approval.
Revenue Prediction The estimize consensus EPS for Q1 2016 is $0.55 and the revenue for the same period is $12,064 million
Social Pulse The stock has 43% lower social chatter than usual.

Continue Reading…